Skip to content

Volatile Organic Compounds as Markers of Acute Rejection in Lung Transplant

Analysis of Volatile Organic Compounds in the Exhaled Air Breath of in Bilateral Lung Transplant Recipients Bi-pulmonary Transplant Patients: Search for Acute Rejection Markers

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03172091
Acronym
VOC-TP
Enrollment
120
Registered
2017-06-01
Start date
2017-06-27
Completion date
2021-10-31
Last updated
2021-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Transplant; Complication, Rejection

Keywords

Lung transplant, Acute resection, Volatile Organic Compounds

Brief summary

The aim of research is to identify markers of acute rejection by VOC analysis in exhaled breath of bilateral-lung transplanted patients. 120 bi-lung transplanted patients will be divided into two groups : patients with acute rejection diagnosed on transbronchial biopsies and patients with no acute rejection. Exhaled breath will be collected for VOC analysis woth electronic nose and mass spectrometry. VOC profiles will be compared between the two groups of patients.

Detailed description

Prospective single-center study. A single visit, no follow-up. The visit will take place before or within five days from date of transbronchial biopsies (BTB). It will include a noninvasive collection of exhaled breath for VOC analysis. VOC analysis will be conducted using two types of devices: electronic nose and mass spectrometry. 200 bi-lung transplanted patients will be enrolled and divided into two groups. * Group A, Acute rejection: 100 patients. Diagnosis of acute rejection retained on transbronchial biopsies or functional anomalies with the necessity of modifying the immunosuppressive regimen. * Group B, control: 100 patients. Patients without respiratory functional abnormality and normal transbronchial biopsy. VOC, detected by electronic nose and identified by mass spectrometry, will be compared between patients with a confirmed diagnosis of acute rejection (group A) and patients without rejection (control group B) The duration of participation of each patient is 1 day. The duration of the inclusion period is estimated at 54 months from the first inclusion. The expected total duration of the research is 54 months

Interventions

DEVICEeNose (electronic nose)

Collection of exhaled breath for an immediate analysis by electronic nose

Collection of exhaled breath for an immediate analysis by mass spectrometry

Sponsors

Hopital Foch
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Bi-pulmonary transplant patient * Acute rejection group: Patients with transbronchial biopsies performed as part of their usual follow-up or for functional abnormality ; Diagnosis of acute rejection retained on the following arguments: histological lesions of cellular rejection or histological lesions of humoral rejection or normal histology but diagnosis of functional rejection retained and immunosuppressive treatment indicated * Control group: Patients benefiting from systematically programmed transbronchial biopsies as part of post-transplant follow-up with normal histology and absence of functional respiratory abnormality

Exclusion criteria

* Patient unable to realize a vital capacity measure * Neoplasia currently treated * Unresolved acute bronchial complication (stenosis or dehiscence) * Immunosuppressive treatment of acute rejection already begun * Patient who has already participated in the protocol and already included in one of the two study groups

Design outcomes

Primary

MeasureTime frameDescription
Volatile Organic Compounds by electronic nose (eNose)1 dayComparison of Volatile Organic Compounds profile detected by electronic nose between lung transplant patients patients with a confirmed diagnosis of acute rejection and patients without rejection

Secondary

MeasureTime frameDescription
Volatile Organic Compounds profile1 dayComparison of Volatile Organic Compounds profile identified by mass spectrometry electronic nose between lung transplant patients with a confirmed diagnosis of acute rejection and patients without rejection
Acute rejection diagnosis1 dayComparison of discriminative capacity for diagnosis of acute rejection between the VOC analysis methods: electronic nose versus mass spectrometry.
Volatile Organic Compounds by spectrometry1 dayDetermining distinct exhaled VOC profiles associated with each type of acute rejection: cellular rejection, humoral rejection or functional rejection

Countries

France

Contacts

Primary ContactHélène Salvator, MD
h.salvator@hopital-foch.com+33(0)046252955

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026